136 related articles for article (PubMed ID: 9376634)
1. The costs of managing advanced colorectal cancer: a broad perspective.
Kerr DJ; O'Connor KM
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S23-6. PubMed ID: 9376634
[TBL] [Abstract][Full Text] [Related]
2. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
Ross P; Heron J; Cunningham D
Eur J Cancer; 1996; 32A Suppl 5():S13-7. PubMed ID: 8958037
[TBL] [Abstract][Full Text] [Related]
3. Raltitrexed in colorectal cancer.
Drug Ther Bull; 1996 Oct; 34(10):78-80. PubMed ID: 8936802
[TBL] [Abstract][Full Text] [Related]
4. Mature results from three large controlled studies with raltitrexed ('Tomudex').
Cunningham D
Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
[TBL] [Abstract][Full Text] [Related]
5. Future developments with 'Tomudex' (raltitrexed).
Van Cutsem E
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S33-8. PubMed ID: 9376636
[TBL] [Abstract][Full Text] [Related]
6. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Sculpher M; Palmer MK; Heyes A
Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.
Groener MG; van Ineveld BM; Byttebier G; van Hout BA; Rutten FF
Anticancer Drugs; 1999 Mar; 10(3):283-8. PubMed ID: 10327033
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer.
Kerr DJ
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S11-5. PubMed ID: 9376632
[TBL] [Abstract][Full Text] [Related]
9. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
Cunningham D; Zalcberg JR; Rath U; Olver I; Van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
Eur J Cancer; 1995 Nov; 31A(12):1945-54. PubMed ID: 8562146
[TBL] [Abstract][Full Text] [Related]
10. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.
Zalcberg J
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S17-22. PubMed ID: 9376633
[TBL] [Abstract][Full Text] [Related]
11. A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes.
Young A; Topham C; Moore J; Turner J; Wardle J; Downes M; Evans V; Kay S
Eur J Cancer Care (Engl); 1999 Sep; 8(3):154-61. PubMed ID: 10763646
[TBL] [Abstract][Full Text] [Related]
12. Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.
Norum J; Balteskard L; Edna TH; Laino R; Wählby L; Rønning G
J Chemother; 2002 Jun; 14(3):301-8. PubMed ID: 12120887
[TBL] [Abstract][Full Text] [Related]
13. Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer.
Aristides M; Chen J; Schulz M; Williamson E; Clarke S; Grant K
Pharmacoeconomics; 2002; 20(11):775-84. PubMed ID: 12201796
[TBL] [Abstract][Full Text] [Related]
14. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
15. 'Tomudex' (raltitrexed) development: preclinical, phase I and II studies.
Judson IR
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S5-9. PubMed ID: 9376637
[TBL] [Abstract][Full Text] [Related]
16. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748
[No Abstract] [Full Text] [Related]
17. Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer.
Farrugia DC; Norman AR; Cunningham D
Eur J Cancer; 1998 Jun; 34(7):987-91. PubMed ID: 9849444
[TBL] [Abstract][Full Text] [Related]
18. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Gunasekara NS; Faulds D
Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].
Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M
Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability.
Thomas RJ; Williams M; Garcia-Vargas J
Clin Oncol (R Coll Radiol); 2003 Aug; 15(5):227-32. PubMed ID: 12924450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
